On March 18, Beijing time, the official website of the drugs patent pool (MPP) in Geneva announced that it had signed agreements with 35 companies, which were allowed to imitate the raw drug or preparation of nimatrilvir, one of the components of paxlovid, an oral drug of Pfizer covid-19. On the 17th, the market rumors of Pfizer covid-19 oral drug imitation license reported by many media were officially confirmed.
the reporter noted that the list includes five pharmaceutical enterprises in China, namely Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) , Apeloa Pharmaceutical Co.Ltd(000739) , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Shanghai deseno, of which Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) only produces APIs, and the rest can produce APIs and preparations at the same time
According to the information on the official website, the drug patent pool organization is a public health organization supported by the United Nations. It is committed to increasing access to life-saving drugs for low – and middle-income countries and promoting drug development.
There are early signs of this authorization. On January 18, Pfizer announced that Pfizer had signed a voluntary license agreement with the pharmaceutical patent pool (MPP) to help expand its accessibility in 95 low – and middle-income countries, accounting for about 53% of the world’s population. But the news did not disclose which companies were involved.
Paxlovid is an oral small molecule covid-19 therapeutic drug. Specifically, it is a combination of pf-07321332 and ritonavir. On February 11, the State Food and Drug Administration announced that in accordance with the relevant provisions of the drug administration law and in accordance with the special drug approval procedures, the emergency review and approval were carried out, and the import registration of the combined packaging of nevitavir tablets / ritonavir tablets (i.e. paxlovid) of Pfizer covid-19 virus treatment drug was approved conditionally.
This is not the first time that Chinese pharmaceutical companies have been authorized to imitate covid-19 oral drugs. On January 20, the pharmaceutical patent pool Organization (MPP) announced through its official website that it had signed an agreement with 27 pharmaceutical companies to allow them to produce and supply molnupiravir, an oral anti covid-19 virus drug of methadone for 105 low-income countries or regions around the world, so as to promote the affordability and accessibility of the drug in the world Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Brightgene Bio-Medical Technology Co.Ltd(688166) , Shijiazhuang Longze pharmaceutical, Shanghai desaino, Langhua pharmaceutical and other five Chinese pharmaceutical enterprises are among them, of which the first four are licensed to produce APIs and finished drugs at the same time, and Langhua pharmaceutical is licensed to produce APIs
Five Chinese pharmaceutical companies can imitate Pfizer’s oral covid-19 drugs, but they still need to pass these hurdles before they can be listed
Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) : licensed to produce covid-19 oral drugs such as nimatovir
Another covid-19 drug “special imitation” list is announced Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , the company is busy expanding its production behind the re authorization of Desano
